Foam cell-derived 4-hydroxynonenal induces endothelial cell senescence in a TXNIP-dependent manner

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 8, 2015, Pages 1887-1899

  Riahi, Yael ^a,b   Kaiser, Nurit ^b   Cohen, Guy ^a   Abd Elrahman, Ihab ^a   Blum, Galia ^a   Shapira, Oz M ^b   Koler, Tomer ^b   Simionescu, Maya ^c   Sima, Anca V ^c   Zarkovic, Neven ^d   Zarkovic, Kamelija ^e   Orioli, Marica ^f   Aldini, Giancarlo ^f   Cerasi, Erol ^b   Leibowitz, Gil ^b   Sasson, Shlomo ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

^d RUDER BO KOVI INSTITUTE   (Croatia)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

TXNIP; VEC; 4 HNE; Atherosclerosis; Foam cells; PPAR ; Senescence

Indexed keywords

BOVINAE;

4-HYDROXY-2-NONENAL; ALDEHYDE; BIOLOGICAL MARKER; CARRIER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SCAVENGER; TXNIP PROTEIN, HUMAN;

ANIMAL; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL MODEL; BOVINE; CELL AGING; CELL LINE; COCULTURE; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; FLUORESCENT ANTIBODY TECHNIQUE; FOAM CELL; HUMAN; LIPID PEROXIDATION; METABOLISM; PATHOLOGY;

ALDEHYDES; ANIMALS; BIOMARKERS; CARRIER PROTEINS; CATTLE; CELL AGING; CELL LINE; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; FOAM CELLS; FREE RADICAL SCAVENGERS; HUMANS; LIPID PEROXIDATION; MODELS, BIOLOGICAL; PLAQUE, ATHEROSCLEROTIC; PPAR DELTA;

EID: 84938216645     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12561     Document Type: Article

References (71)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
2. Chiu JJ, Usami S, Chien S. Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann Med. 2009; 41: 19-28.
3. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011; 91: 327-87.
4. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005; 66: 286-94.
5. Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 1993; 88: 77-81.
6. Hatake K, Kakishita E, Wakabayashi I, et al. Effect of aging on endothelium-dependent vascular relaxation of isolated human basilar artery to thrombin and bradykinin. Stroke. 1990; 21: 1039-43.
7. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 2009; 335: 165-89.
8. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995; 91: 1981-7.
9. Nakamura T, Takano H, Umetani K, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis. 2005; 181: 321-7.
10. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology. 2006; 13: 129-42.
11. Hotamisligil GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med. 2010; 16: 396-9.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.
13. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006; 1: 297-329.
14. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007; 100: 15-26.
15. Erusalimsky JD. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol. 2009; 106: 326-32.
16. Hayflick L. Living forever and dying in the attempt. Exp Gerontol. 2003; 38: 1231-41.
17. Goligorsky MS, Chen J, Patschan S. Stress-induced premature senescence of endothelial cells: a perilous state between recovery and point of no return. Curr Opin Hematol. 2009; 16: 215-9.
18. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995; 81: 323-30.
19. Fenton M, Barker S, Kurz DJ, et al. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol. 2001; 21: 220-6.
20. Ota H, Eto M, Kano MR, et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1634-9.
21. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol. 2006; 290: H1729-39.
22. Hayashi T, Yano K, Matsui-Hirai H, et al. Nitric oxide and endothelial cellular senescence. Pharmacol Ther. 2008; 120: 333-9.
23. Burrig KF. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler Thromb Vasc Biol. 1991; 11: 1678-89.
24. Dierick JF, Eliaers F, Remacle J, et al. Stress-induced premature senescence and replicative senescence are different phenotypes, proteomic evidence. Biochem Pharmacol. 2002; 64: 1011-7.
25. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006; 37: 208-22.
26. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002; 8: 1235-42.
27. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98: 2572-9.
28. Jaganjac M, Tirosh O, Cohen G, et al. Reactive aldehydes-second messengers of free radicals in diabetes mellitus. Free Radic Res. 2013; 47: 39-48.
29. Riahi Y, Cohen G, Shamni O, et al. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab. 2010; 299: E879-86.
30. Cohen G, Riahi Y, Sasson S. Lipid peroxidation of poly-unsaturated fatty acids in normal and obese adipose tissues. Arch Physiol Biochem. 2011; 117: 131-9.
31. Cohen G, Riahi Y, Sunda V, et al. Signaling properties of 4-hydroxyalkenals formed by lipid peroxidation in diabetes. Free Radic Biol Med. 2013; 65: 978-87.
32. Leonarduzzi G, Chiarpotto E, Biasi F, et al. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res. 2005; 49: 1044-9.
33. Barrera G, Pizzimenti S, Dianzani MU. 4-hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway. Free Radic Biol Med. 2004; 37: 597-606.
34. Poot M, Esterbauer H, Rabinovitch PS, et al. Disturbance of cell proliferation by two model compounds of lipid peroxidation contradicts causative role in proliferative senescence. J Cell Physiol. 1988; 137: 421-9.
35. Dalleau S, Baradat M, Gueraud F, et al. Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ. 2013; 20: 1615-30.
36. Usatyuk PV, Natarajan V. Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res. 2012; 83: 45-55.
37. Vladykovskaya E, Sithu SD, Haberzettl P, et al. Lipid peroxidation product 4-hydroxy-trans-2-nonenal causes endothelial activation by inducing endoplasmic reticulum stress. J Biol Chem. 2012; 287: 11398-409.
38. Vatsyayan R, Kothari H, Pendurthi UR, et al. 4-Hydroxy-2-nonenal enhances tissue factor activity in human monocytic cells via p38 mitogen-activated protein kinase activation-dependent phosphatidylserine exposure. Arterioscler Thromb Vasc Biol. 2013; 33: 1601-11.
39. Spickett CM. The lipid peroxidation product 4-hydroxy-2-nonenal: advances in chemistry and analysis. Redox Biol. 2013; 1: 145-52.
40. Poli G, Schaur RJ, Siems WG, et al. 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev. 2008; 28: 569-631.
41. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med. 2004; 37: 937-45.
42. Cohen G, Riahi Y, Shamni O, et al. Role of lipid peroxidation and PPAR-delta in amplifying glucose-stimulated insulin secretion. Diabetes. 2011; 60: 2830-42.
43. Coleman JD, Prabhu KS, Thompson JT, et al. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med. 2007; 42: 1155-64.
44. Riahi Y, Sin-Malia Y, Cohen G, et al. The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta. Diabetes. 2010; 59: 808-18.
45. Altschmied J, Haendeler J. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid Redox Signal. 2009; 11: 1733-40.
46. Mahmood DF, Abderrazak A, El Hadri K, et al. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013; 19: 1266-303.
47. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res. 2003; 93: 1029-33.
48. Dunn LL, Buckle AM, Cooke JP, et al. The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol. 2010; 30: 2089-98.
49. Li X, Rong Y, Zhang M, et al. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun. 2009; 381: 660-5.
50. Wang XQ, Nigro P, World C, et al. Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2. Circ Res. 2012; 110: 560-8.
51. Go YM, Halvey PJ, Hansen JM, et al. Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion. Am J Pathol. 2007; 171: 1670-81.
52. Shaked M, Ketzinel-Gilad M, Cerasi E, et al. AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cells. PLoS ONE. 2011; 6: e28804.
53. Sima AV, Botez GM, Stancu CS, et al. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J Cell Mol Med. 2010; 14: 2790-802.
54. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993; 42: 80-9.
55. Orioli M, Aldini G, Benfatto MC, et al. HNE Michael adducts to histidine and histidine-containing peptides as biomarkers of lipid-derived carbonyl stress in urines: LC-MS/MS profiling in Zucker obese rats. Anal Chem. 2007; 79: 9174-84.
56. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology. 2005; 146: 2397-405.
57. Aldini G, Vistoli G, Orioli M, et al. Discovery of FL-926-16, a bioavailable carnosine analogue, effective in metabolic syndrome and diabetes-related disorders. J Diabetes. 2013; 5: 90-1.
58. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev. 2013; 93: 1803-45.
59. El Hadri K, Mahmood DF, Couchie D, et al. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 1445-52.
60. Yamawaki H, Pan S, Lee RT, et al. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest. 2005; 115: 733-8.
61. Grondin CM, Campeau L, Lesperance J, et al. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. Circulation. 1984; 70: I208-12.
62. Loop FD. Internal-thoracic-artery grafts. Biologically better coronary arteries. N Engl J Med. 1996; 334: 263-5.
63. Ungvari Z, Kaley G, de Cabo R, et al. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010; 65: 1028-41.
64. Chapple SJ, Cheng X, Mann GE. Effects of 4-hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease. Redox Biol. 2013; 1: 319-31.
65. Fang J, Holmgren A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J Am Chem Soc. 2006; 128: 1879-85.
66. Wakita C, Maeshima T, Yamazaki A, et al. Stereochemical configuration of 4-hydroxy-2-nonenal-cysteine adducts and their stereoselective formation in a redox-regulated protein. J Biol Chem. 2009; 284: 28810-22.
67. Briganti S, Flori E, Mastrofrancesco A, et al. Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARgamma. Exp Dermatol. 2013; 22: 41-7.
68. Shearer BG, Steger DJ, Way JM, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol. 2008; 22: 523-9.
69. World CJ, Yamawaki H, Berk BC. Thioredoxin in the cardiovascular system. J Mol Med. 2006; 84: 997-1003.
70. Brodsky SV, Gealekman O, Chen J, et al. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res. 2004; 94: 377-84.
71. Zhang X, Li J, Sejas DP, et al. The ATM/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells. J Biol Chem. 2005; 280: 19635-40.